The new macrolide antibiotics. Azithromycin and clarithromycin

Area of Science:

• Pharmacology
• Infectious Diseases
• Microbiology

Background:

• Erythromycin, a traditional macrolide, has limitations in spectrum and tolerability.
• Newer macrolide antibiotics, azithromycin and clarithromycin, have emerged with distinct advantages.
• Understanding their pharmacokinetic and pharmacodynamic profiles is crucial for optimizing treatment.

Purpose of the Study:

• To compare the clinical advantages of azithromycin and clarithromycin over erythromycin.
• To evaluate the antimicrobial spectrum, tissue penetration, and bioavailability of these new agents.
• To review their efficacy in treating common bacterial infections.

Main Methods:

• Comparative analysis of pharmacokinetic and pharmacodynamic properties.
• Review of clinical trial data for efficacy and safety.
• Assessment of antimicrobial activity against key pathogens.

Main Results:

• Azithromycin exhibits an expanded spectrum against gram-negative bacilli.
• Clarithromycin shows enhanced activity against gram-positive cocci, further improved by its metabolite.
• Both agents demonstrate excellent tissue penetration, concentration in immune cells, improved bioavailability, and extended half-lives, enabling shorter treatment durations.
• Effective in treating streptococcal pharyngitis, sinusitis, respiratory tract infections, skin infections, and STDs.
• Azithromycin effective as a single dose for genital chlamydial infections.
• Adverse reactions are typically mild, with lower discontinuation rates than erythromycin.

Conclusions:

• Azithromycin and clarithromycin represent significant advancements in macrolide antibiotic therapy.
• Their favorable pharmacokinetic profiles and broad efficacy support their use in various infectious diseases.
• Continued evaluation will define their long-term role in clinical practice.